The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-07-24
DOI
10.3389/fonc.2020.01249
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The biology, function, and biomedical applications of exosomes
- (2020) Raghu Kalluri et al. SCIENCE
- Long noncoding RNA and mRNA profiling in cetuximab-resistant colorectal cancer cells by RNA sequencing analysis
- (2019) Changwen Jing et al. Cancer Medicine
- Exosomes in the tumor microenvironment as mediators of cancer therapy resistance
- (2019) Irene Li et al. Molecular Cancer
- Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
- (2019) Robert L. Ferris et al. CLINICAL CANCER RESEARCH
- CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
- (2019) Bryan D. Choi et al. NATURE BIOTECHNOLOGY
- Microenvironment plasticity confers cetuximab resistance
- (2019) Peter Sidaway Nature Reviews Clinical Oncology
- Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential
- (2019) Mohammad-Hossein Haddadi et al. BLOOD REVIEWS
- Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer
- (2018) Ke Peng et al. BIOMEDICINE & PHARMACOTHERAPY
- CRISPR/Cas9 genome editing technology significantly accelerated herpes simplex virus research
- (2018) Dong Wang et al. CANCER GENE THERAPY
- Final Analysis of Outcomes and RAS / BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer
- (2018) Tae Won Kim et al. Clinical Colorectal Cancer
- Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer
- (2018) Tudor Ciuleanu et al. Clinical Lung Cancer
- PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study
- (2018) Arndt Vogel et al. EUROPEAN JOURNAL OF CANCER
- Oncolytic Viruses for Tumor Precision Imaging and Radiotherapy
- (2018) Zi J. Wu et al. HUMAN GENE THERAPY
- Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study
- (2018) Roy S Herbst et al. LANCET ONCOLOGY
- OUP accepted manuscript
- (2018) NEURO-ONCOLOGY
- Nimotuzumab: beyond the EGFR signaling cascade inhibition
- (2018) Zaima Mazorra et al. SEMINARS IN ONCOLOGY
- Structural considerations for functional anti-EGFR × anti-CD3 bispecific diabodies in light of domain order and binding affinity
- (2018) Ryutaro Asano et al. Oncotarget
- Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers
- (2018) Rebecca W. Gao et al. Theranostics
- Necitumumab for the treatment of advanced non-small-cell lung cancer
- (2018) Asunción Díaz-Serrano et al. Future Oncology
- Immune Effector Functions of Human IgG2 Antibodies against EGFR
- (2018) Thies Rösner et al. MOLECULAR CANCER THERAPEUTICS
- The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme
- (2017) Dimitry A. Chistiakov et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- CD44+ fibroblasts increases breast cancer cell survival and drug resistance via IGF2BP3-CD44-IGF2 signalling
- (2017) Yonglei Liu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells
- (2017) Biljana Petrovic et al. JOURNAL OF VIROLOGY
- lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling
- (2017) Yuanyuan Lu et al. NATURE MEDICINE
- Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
- (2017) Zaima Mazorra et al. Frontiers in Pharmacology
- Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K 521 Polymorphism
- (2016) Friederike Braig et al. CANCER RESEARCH
- Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial
- (2016) Ming Lu et al. CANCER SCIENCE
- The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
- (2016) F. J. Sanchez-Martin et al. CLINICAL CANCER RESEARCH
- Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
- (2016) S. Trivedi et al. CLINICAL CANCER RESEARCH
- MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
- (2016) Sabrina Arena et al. Science Translational Medicine
- Retargeting Strategies for Oncolytic Herpes Simplex Viruses
- (2016) Gabriella Campadelli-Fiume et al. Viruses-Basel
- Oncogenic MET as an Effective Therapeutic Target in Non-Small Cell Lung Cancer Resistant to EGFR Inhibitors: The Rise of the Phoenix
- (2016) L. Trusolino Cancer Discovery
- A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
- (2016) Hye Ryun Kim et al. Oncotarget
- Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin
- (2016) Hong-Wu Xin et al. Journal of Cancer
- Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
- (2016) Jérôme Fayette et al. Frontiers in Oncology
- A Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor
- (2015) Erika Kovacs et al. Annual Review of Biochemistry
- Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
- (2015) Said A Khelwatty et al. BRITISH JOURNAL OF CANCER
- A phase 1 study of ABT-806 in subjects with advanced solid tumors
- (2015) James M. Cleary et al. INVESTIGATIONAL NEW DRUGS
- PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response
- (2015) Hsin-Wei Liao et al. JOURNAL OF CLINICAL INVESTIGATION
- The genomic landscape of response to EGFR blockade in colorectal cancer
- (2015) Andrea Bertotti et al. NATURE
- AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer
- (2015) Teraneh Z. Jhaveri et al. Oncotarget
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- MicroRNA-7expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity viaEGFRregulation
- (2014) Toshinaga Suto et al. CARCINOGENESIS
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- (2014) Timothy J Price et al. LANCET ONCOLOGY
- Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
- (2014) N. C. Singha et al. MOLECULAR CANCER THERAPEUTICS
- Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients
- (2014) B.K.M. Reddy et al. ORAL ONCOLOGY
- Cetuximab Induces Eme1-Mediated DNA Repair: a Novel Mechanism for Cetuximab Resistance
- (2014) Agnieszka Weinandy et al. NEOPLASIA
- Label-retaining liver cancer cells are relatively resistant to sorafenib
- (2013) Hong-Wu Xin et al. GUT
- Design and development of therapies using chimeric antigen receptor-expressing T cells
- (2013) Gianpietro Dotti et al. IMMUNOLOGICAL REVIEWS
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nuclear EGFR as a molecular target in cancer
- (2013) Toni M. Brand et al. RADIOTHERAPY AND ONCOLOGY
- Wnt and the Cancer Niche: Paracrine Interactions with Gastrointestinal Cancer Cells Undergoing Asymmetric Cell Division
- (2013) Hong-Wu Xin et al. Journal of Cancer
- Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer
- (2012) Javier Rodríguez et al. EUROPEAN JOURNAL OF CANCER
- Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies
- (2012) Lisa Licitra et al. EUROPEAN JOURNAL OF CANCER
- Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas
- (2012) Tanja Trarbach et al. INVESTIGATIONAL NEW DRUGS
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
- (2012) Sandra Misale et al. NATURE
- Tumor-Initiating Label-Retaining Cancer Cells in Human Gastrointestinal Cancers Undergo Asymmetric Cell Division
- (2012) Hong-Wu Xin et al. STEM CELLS
- Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
- (2011) B. P. Pollack et al. CLINICAL CANCER RESEARCH
- Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer
- (2011) Tadaaki Yamada et al. Journal of Thoracic Oncology
- Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
- (2011) Jean-Pascal Machiels et al. LANCET ONCOLOGY
- Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab
- (2010) Deric L. Wheeler et al. CANCER BIOLOGY & THERAPY
- Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
- (2010) Jolien Tol et al. EUROPEAN JOURNAL OF CANCER
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin
- (2010) Melarkode S. Ramakrishnan et al. mAbs
- Understanding resistance to EGFR inhibitors—impact on future treatment strategies
- (2010) Deric L. Wheeler et al. Nature Reviews Clinical Oncology
- Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
- (2009) E. Martinelli et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance
- (2009) J. Nevo et al. CLINICAL CANCER RESEARCH
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- (2009) Pierre Laurent-Puig et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
- (2009) James A Bonner et al. LANCET ONCOLOGY
- Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
- (2009) Nicola Normanno et al. Nature Reviews Clinical Oncology
- Effect of Recombinant Adenovirus-p53 Combined With Radiotherapy on Long-Term Prognosis of Advanced Nasopharyngeal Carcinoma
- (2008) Jian-ji Pan et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
- (2008) D L Wheeler et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started